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Abstract. Therapeutic proteins (TPs) are increasingly combined with small molecules and/or with other
TPs. However preclinical tools and in vitro test systems for assessing drug interaction potential of TPs
such as monoclonal antibodies, cytokines and cytokine modulators are limited. Published data suggests
that clinically relevant TP-drug interactions (TP-DI) are likely from overlap in mechanisms of action,
alteration in target and/or drug-disease interaction. Clinical drug interaction studies are not routinely
conducted for TPs because of the logistical constraints in study design to address pharmacokinetic (PK)-
and pharmacodynamic (PD)-based interactions. Different pharmaceutical companies have developed
their respective question- and/or risk-based approaches for TP-DI based on the TP mechanism of action
as well as patient population. During the workshop both company strategies and regulatory perspectives
were discussed in depth using case studies; knowledge gaps and best practices were subsequently
identiﬁed and discussed. Understanding the functional role of target, target expression and their
downstream consequences were identiﬁed as important for assessing the potential for a TP-DI.
Therefore, a question-and/or risk-based approach based upon the mechanism of action and patient
population was proposed as a reasonable TP-DI strategy. This ﬁeld continues to evolve as companies
generate additional preclinical and clinical data to improve their understanding of possible mechanisms
for drug interactions. Regulatory agencies are in the process of updating their recommendations to
sponsors regarding the conduct of in vitro and in vivo interaction studies for new drug applications
(NDAs) and biologics license applications (BLAs).
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INTRODUCTION
Therapeutic proteins (TPs) such as monoclonal anti-
bodies (mAbs) are increasingly being combined with small
molecule drugs (SMDs) and other TPs to treat various
diseases including immune-mediated diseases and cancer.
The Food and Drug Administration (FDA) recently high-
lighted the potential and importance of therapeutic protein–
drug interactions (TP-DI; 1,2). Other review papers have also
recently been published on TP-DI (3–5). As TPs are not
metabolized by cytochrome P450 (CYP) enzymes or trans-
ported by transporters and biotransformation studies have
not been routinely conducted, it was assumed that TPs do not
cause metabolism-based drug interactions (DI). However,
recent reports suggest that the use of cytokines, cytokine
modulators such as anti-cytokine mAb or immunosuppressant
containing drug combinations, in inﬂammatory indications,
can lead to CYP-mediated DI, with the SMD as the victim
(5,6). Many TPs, cytokines, or cytokine modulators (antago-
nists) have been shown to alter CYP or transporter activities
through direct or indirect effects.
In vitro strategies for assessing TP-DI during drug
development are limited. Because of inherent differences in
metabolic pathways between TPs and SMDs, few preclinical
or in vitro tools commonly used for DI assessment for SMDs
can be readily adopted to predict DI for TPs. There are also
constraints in designing appropriate clinical DI studies due to
pharmacokinetic (PK) properties of TPs.
The FDA’s Draft Drug Interaction Guidance published
in 2006, titled “Drug Interaction Studies—Study Design, Data
Analysis and Implications for Dosing and Labeling” states
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required for biologics because they are not metabolized by
metabolizing enzymes (7). The guidance however raises
concerns regarding potential interactions between TPs and
SMDs such as interferons and SMDs or between two different
TPs. The guidance also states that in vitro methods may not be
suitable. Two recent publications from the FDA highlight the
current perspectives on TP-DI, particularly those involving
effect of cytokine modulators on CYPs (1,2). The European
Medicines Agency guidance published in July 2007 titled
“Guideline on the Clinical Investigation of the Pharmacoki-
netics of Therapeutic Proteins” supports concerns about immu-
nomodulators such as cytokines that have shown a potential for
the inhibition or induction of CYP enzymes thereby altering the
metabolism of SMDs metabolized by these enzymes (8).
It is critical to understand the possible DI mechanisms
for TPs and build a strategy during drug development to
ensure safe and effective use of therapeutics. An American
Association of Pharmaceutical Scientists-sponsored workshop
was organized
1,2 to address limitations and knowledge gaps in
assessing the potential for TP-DI, to share drug development,
research and regulatory experience in TP-DI assessment, and
to develop strategies for assessing TP-DI during drug
development. Participants included industry, academic, and
regulatory representatives.
GOALS AND OBJECTIVES
This workshop aimed to provide participants with a clear
understanding on how to develop strategies for assessing TP-
DI during drug development by:
& reviewing preclinical tools and in vitro test systems
for assessing the DI potential of TPs such as
cytokines and cytokine modulators,
& reviewing literature on clinically relevant TP-DI,
& discussing study designs and acceptance criteria for
assessing PK- and pharmacodynamic (PD)-based TP-
DI in clinical studies, and
& providing participants with the knowledge and skills
to develop a science driven approach for assessing
the risk and potential of TP-DI.
This paper condenses the salient points, considerations,
and positions presented and discussed during the workshop
providing a sense of the state-of-the-art with respect to TP-DI
exploration.
SESSION I: PROLOG—IN VITRO AND PRECLINICAL
MODELS AND CURRENT STATUS
Preclinical Tools and In Vitro Test Systems to Assess TP-DI
Potential during Drug Development
In vitro studies with isolated human hepatocytes or liver
microsomes generally provide insight into the PK DI
potential for co-administered SMDs. In contrast, it is
currently not feasible to predict the propensity for DI
between TPs and SMDs. Although the effects in general
have been weak to moderate, examples of DI between TPs
and SMDs have been observed, particularly for cytokines.
Based on clinical data with interferons and interleukins (9–
13), two important conclusions can be drawn: (1) cytokines
can cause the downregulation of a wide range of CYP or
isoform speciﬁc CYP enzymes, (2) a high inter-individual
variability in effects on CYP levels is observed. Complicating
factors in interpreting clinical DI data with cytokines include:
(1) variability in the dose and duration of treatment, (2)
whether the study was conducted in healthy volunteers or in
patients, and (3) use of non-standardized probe substrates to
monitor CYP activities.
In contrast to the straightforward evaluation of in vitro
hepatocyte data for SMD DI, in vitro TP DI data have proven
to be more difﬁcult to interpret (2). For example, although a
high dose of interleukin (IL)-2 has shown decreased CYP3A4
and other CYP activities in human liver (12), this ﬁnding
could not be reproduced in vitro using hepatocytes. However,
a sustained downregulation was observed in hepatocytes co-
cultured with Kupffer cells (14), suggesting that IL-2 causes
Kupffer cells to secrete a cytokine, which indirectly down-
regulates CYP3A4 in hepatocytes. Complex signaling may be
often involved in TP-DI and it is not currently possible to
assure that cell culture systems provide the appropriate mix
of cell types required for meaningful evaluation in vitro.A s
such, relatively little is known about the effects of TPs on
CYPs, and little is known about the effects of TPs on other
drug metabolizing enzymes or drug transporters. Recent
work has demonstrated that TNF-α and IL-6 reduce the
protein levels and activity of several drug transporters,
supporting the contention that there is a clear need for
additional investigation (15).
The observation that different cytokines can have differ-
ential effects on the various CYP enzymes suggests that there
are multiple mechanisms which could result in reducing
enzyme activities (16).
With current knowledge and technology, it is not feasible
to make prospective predictions based on in vitro hepatocyte
data whether cytokines have the propensity to cause DI with
SMDs. An important step towards establishing whether this
might be possible in the future would require systematic
retrospective analysis using standardized assay conditions,
and the identiﬁcation of suitable positive controls to monitor
assay performance.
A Recent Biotechnology Industry Organization (BIO)
Survey on TP-DI Evaluation during Development of TPs
Because of emerging science and lack of clear regulatory
guidance, there is a perception that substantial inconsistencies
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ical/biotechnology companies. Recently, the BioSafe Pharma-
cokinetics and Disposition Expert Working Group completed
a survey to better understand “current practices” as to when a
DI assessment strategy should be incorporated into TP drug
development programs. Twenty-one companies representing
a comprehensive cross-section of the BIO organization
participated in the survey. Unlike SMD-DI studies, in vitro
and preclinical methods are not widely used for DI assess-
ments of TPs. As a result, clinical methods are still primarily
used for these assessments. Three methods are commonly
employed: (1) dedicated DI studies, (2) population pharma-
cokinetics-based assessments, and (3) clinical cocktail studies.
Survey results indicated that most of the observed DI
involving TPs was not clinically relevant, i.e., did not result
in dose adjustment. In several companies, science-driven,
risk-based strategies are being applied to incorporate DI
assessments for TP drug development. However, it is unclear
from the survey whether other companies are currently
developing similar strategies or intend to do so in the future.
A future follow-up survey will attempt to address these
topics, among others.
SESSION II: INDUSTRY PERSPECTIVES ON TP-DI
EVALUATION: CASE STUDIES AND STRATEGIES
To evaluate current practices in industry, speakers from
four companies with diverse experience in developing TPs
presented challenges and strategies in assessing TP-DI with
case examples and insights on how approaches were devel-
oped to address risk-based assessment of TP-DI. Examples
were largely restricted to mAbs due to limited information
available on other classes of TPs.
Amgen’s Integrated Approach to Assess TP-DI in Cancer
Treatment
The safety proﬁle of drug combinations is critical for
balancing treatment beneﬁt and risk in cancer patients. Four
selected TPs approved for cancer treatment, namely bevaci-
zumab, trastuzumab, panitumumab, and cetuximab were used
as examples. A literature review of 80 journal articles and
conference abstracts revealed that TP-DI potential was
evaluated in only one third of the clinical trials. Most results
were either negative for DI or showed less than 30% change
in mean drug exposure with large intersubject variability. In
general, TP exposure was not affected in the presence of
SMDs. Based on the literature data on these four cancer TPs,
no interaction has been reported between TPs and no TP
dose adjustments have been warranted.
TP-DI evaluation is usually not a stand-alone study but
rather a substudy evaluation conducted as part of ongoing
phase 2/3 clinical trials. As a result, conventional “well-
controlled” DI study conditions (e.g., control diet, co-
medications, disease status, treatment options, dosing time,
and schedule) are hardly preserved. TP PK data is usually less
intensive than those with traditional study designs for SMD-
DI studies. The number of subjects may not be well balanced
across treatment cycles or arms, and the number of evaluable
subjects is also affected by unscheduled dose and sampling
time due to dose interruption/reduction or patient discontin-
uation. Challenges also exist in non-compartmental PK
analysis as there are often a signiﬁcant number of data
exclusions. PK assessments are further complicated as many
TPs in oncology have non-linear pharmacokinetics. More-
over, since a TP-alone arm is uncommon in an oncology
setting, historical data are usually referenced in the TP-DI
evaluation. Therefore, a scientiﬁcally sound and technically
feasible integrated TP-DI evaluation strategy needs to be
developed to address these challenges.
It is preferable to include TP-DI assessment in early
phase 1b/2 trials because they are relatively small in size and
operational issues are more easily addressed. Importantly, the
early TP-DI data can help establish development strategies
and also guide later phase study designs. If any TP-DI signals
are identiﬁed in small early trials, expanded assessment can
be considered. One limitation of early assessment is that the
optimal drug combination is often modiﬁed in later stages of
development. Although testing TP-DI in late phase for
product registration is possible, it increases the complexity
of pivotal phase 3 trials and is thus likely to have more
confounding factors that can contribute to difﬁculty in data
interpretation.
SelectinginteractingdrugsforTP-DIinvestigationismainly
based on potential concomitant usage, PK and PD properties
and thetherapeuticwindowof selected drugs.ForevaluatingPK
interaction, commonly used study designs include:
1. one-sequence crossover design (e.g., chemotherapy
followed by chemotherapy+TP to test TP effect on
chemotherapy; testing effect of chemotherapy on TP
may need cross-study comparison);
2. parallel design (e.g., TP+chemotherapy vs. chemo-
therapy alone to test the effect of TP on chemo-
therapy; testing effect of chemotherapy on TP may
need cross-study comparison) and
3. a one-way sequential phase 1b study (open label)
staggered with a phase 2 (double blind) study.
Design selection should be based on the PK properties of
the interacting drugs as well as the types of interaction.
TP-DI evaluation is usually conducted as an estimation
study with 10–20 patients per arm in either a PK subgroup
study of phase 2/3 trial or in a phase 1b study. Due to large
inter-subject variability in exposure for TP in oncology, fully
powered TP-DI studies for hypothesis test are uncommon.
Depending on the pharmacokinetics, intensive PK sampling
has been collected for the chemo-agents and relative sparse
PK sampling for TPs due to their much longer half-lives.
Combined intensive and sparse sampling schemes may be
collected in cycle 1 and at steady state. To evaluate the
clinical relevance of any change in exposure (e.g., AUC,
Cmax,o rC min), safety, PD, and efﬁcacy measures may be
collected along with the PK samples. If an interaction is
observed, clinical relevance should be evaluated in conjunc-
tion with safety and efﬁcacy data and should be the primary
consideration in data interpretation.
Non-compartment analysis and/or population modeling
approaches may be applicable to TP-DI evaluation. Covariate
analysis may be used to identify potential contributing factors
to drug exposure, as well as testing for study effects in cross-
study comparisons. The importance of the DI will be
determined by the therapeutic index of the drug combination.
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extremely useful to aid systematic planning in design of TP-
DI studies across programs. For example, using a stand-
ardized approach to collect PK data for a speciﬁc chemo-
therapy regimen (e.g., paclitaxel) from control arms in
different studies was extremely useful in the interpretation
of results in new TP–drug combination studies.
Amgen thus presented an integrated approach as used in
an oncology setting with speciﬁc details around timing of such a
study, type of DI studies based on stage of drug development
and DI signal in early studies. Modeling- and simulation-based
TP-DI evaluation was used to address speciﬁc challenges.
Genentech’s Question- and Risk-Based Approach to Assess
TP-DI
The Genentech presentation provided an overview of
potential mechanisms for TP-related DI, both PK and PD
examplesfocusedonmAbtherapeutics,oneofmanyTPclasses.
This approach may also be applied to other TPs. The proposed
question- and risk-based approach assesses both effect of other
therapeutics on TPs and effect of TPs on other drugs.
A systematic approach to answering the question of
“Can a therapeutic mAb be either a victim or a perpetrator of
a TP-DI?” assesses the clearance mechanisms of a particular
mAb and asks whether extrinsic factors such as co-adminis-
tered TPs or SMDs can affect these clearance processes.
These clearance mechanisms can be classiﬁed under the
following categories:
Speciﬁc mechanisms governed by target biology—these
are typically high afﬁnity, low capacity saturation processes
like binding of mAbs to its target and subsequent target-
mediated clearance. The biology of the target, including
information on the site of expression, relative abundance of
expression, and the pharmacology of the target are all
important in assessing whether a TP or SMD in combination
with a mAb can alter mAb pharmacokinetics. Speciﬁc
examples of such PD interactions where target biology is
altered are efalizumab in combination with triple immuno-
suppressant therapy (17) and anakinra in combination with
etanercept (18). Both combinations resulted in PD-based
interactions. In contrast, no alteration in target biology was
anticipated and no interaction was noted for bevacizumab in
combination with erlotinib (19).
Non-speciﬁc mechanisms that are typically governed by
immunoglobulin structure are high-capacity, largely nonsatur-
able processes like neonatal Fc receptor (FcRn) recycling,
non-speciﬁc uptake by tissues, binding to Fcγ receptors, and
proteolytic degradation. There is a high expression of FcRn
and Fcγ receptors, and theoretically very high concentrations
of IgG can saturate the FcRn receptors. However, the
concentration required is far higher than circulating IgG
levels and therapeutic levels of mAbs (for example, endog-
enous IgG levels in normal individuals are about 10 mg/mL
while therapeutic levels of mAbs are in microgram per
milligram range and at these concentrations FcRn is not
saturable). To date, there appears to be limited evidence of a
DI mediated by non-speciﬁc clearance mechanism for mAbs
in combination. Speciﬁc examples of mAb combinations
where no alteration in PK was observed are trastuzumab
combined with bevacizumab (20) and rituximab combined
with bevacizumab (21). However, it is worth noting that a
downregulation of Fcγ receptors by methotrexate (MTX) is
observed in patients with rheumatoid arthritis (RA). It is
plausible that the change in Fcγ receptors in the presence of
MTX may affect mAb clearance during mAb treatment in
combination with MTX in RA patients (22,23).
Immunogenicity to TP may enhance clearance from the
body. Some evidence exists suggesting an impact of immuno-
suppressive agents on mAb pharmacokinetics, possibly due to
alteration in target (expression or cell number) and/or
reduced immunogenicity. An apparent DI (i.e., decrease in
mAb clearance) was noted when a combination with MTX
was noted for inﬂiximab (23) and adalimumab (24). This was
attributed to MTX’s immunosuppressive effect, decreasing
immune response to the mAb. Additionally, the immunoge-
nicity of anti-TNF-α agents in autoimmune diseases has been
recently reviewed (25).
Tertiary carbohydrate structure can theoretically mediate
clearance through carbohydrate-speciﬁc clearance mecha-
nisms. However, no speciﬁc example of TP-DI has been cited
for this possible mechanism.
TPs such as cytokines and cytokine modulators are likely to
affect the pharmacokinetics of a SMD. Therefore, special
attention should be given to narrow therapeutic range (NTR)
drugs in combination with cytokine/cytokine modulators. Two
additional categories of DI following combination of cytokines
and cytokine modulators with SMDs are further discussed below:
1. TP is a cytokine or a cytokine modulator and there-
fore affects SMD metabolism (1). When muromonab
and Cyclosporin A (CsA) (26) were given in combi-
nation there was an increase in CsA trough levels. The
suggested mechanism for this is T-cell activation and
subsequent release of multiple cytokines such as IL-2,
IL-3, TNFα, and TNFγ. Similarly, an increase in
trough level of tacrolimus was observed in combina-
tion with basiliximab (27) and an increase in CsA
levels when combined with basiliximab (28). For both
of these interactions, an indirect mechanism is sug-
gested. Binding of the mAb to IL-2R on activated T-
cells may alter circulating IL-2Rs on hepatic and
intestinal cells and could possibly result in down-
regulation of CYP3A4 enzyme activity. Potential DI
mediated by such indirect mechanisms is a concern
and currently, precautionary language exists in United
States Prescribing Information for cytokine modula-
tors, rilonacept, canakinumab, golimumab, and uste-
kinumab (29–32).
2. Drug–disease interaction is a mechanism whereby
treatment with a cytokine or cytokine modulator
could normalize previously downregulated CYP
enzymes. This is illustrated conceptually by Morgan
(6) and has been demonstrated in an in vivo DI study
for tocilizumab+omeprazole and tocilizumab+simvas-
tatin drug combinations but not for tocilizumab+
dextromethorphan (33). A decrease in omeprazole
(28%) and simvastatin (57%) exposure was observed
when combined with tocilizumab.
As also highlighted by the Amgen speaker that there
are considerable logistical constraints and operational
408 Girish et al.challenges when assessing TP-DI in the clinical setting
especially in oncology. Therefore, dedicated DI studies in
patients are not always possible. A dedicated TP-DI study
was conducted to study irinotecan+bevacizumab when a
DI alert was generated in a phase 3 study with this
combination. The dedicated DI study (34) however showed
that there was no effect of bevacizumab on irinotecan or
SN-38 levels. In other clinical studies as well, to date, no
PK interactions have been observed between bevacizumab
and any of the following agents: capecitabine, cisplatin, 5-
ﬂuorouracil, irinotecan, oxaliplatin, paclitaxel, interferon
alfa-2a, or trastuzumab.
On the practical level, when applying this historical
knowledge to evolve a TP-DI strategy for a mAb in
development, it is clear that an individualized and iterative
approach is warranted. Genentech’s question-based risk
assessment DI strategy as applied to therapeutic mAbs in
development is summarized in Fig. 1.T h i sp r o c e s si s
incorporated into the clinical pharmacology plan in the
early stages of development and utilizes a scientiﬁc
approach to assessing potential mechanisms for TP-DI risk
in the context of type of molecule, indication, pharmaco-
kinetics, pharmacodynamics, study design considerations,
immunogenicity, drug combinations, therapeutic index of
drug, etc. A thorough knowledge of all of the aforemen-
tioned components will help determine the need for DI
assessment and for data collection on a case-by-case basis
when a mAb is combined with a SMD and/or with another
mAb. If DI assessment is scientiﬁc a l l yr e a s o n a b l e ,t h er i s k
assessment strategy is expected to guide the design and
conduct of the appropriate study.
As illustrated in Fig. 1, Genentech may conduct DI
analyses in phase 1b or 2 or phase 3 clinical studies for
select new molecular entities if the results of a DI risk
assessment leads Genentech to believe that a safety or
efﬁcacy risk exists for a treatment combination. For
molecules exhibiting a clinically relevant DI signal, addi-
tional conﬁrmatory analyses may be conducted in phase 3
studies.
Risk-Based Approach to Assess Potential for TP-DI
in Biogen Idec
When considering DI, maintaining patient safety and
drug efﬁcacy is paramount. In addition to ethical concerns,
clinical DI studies can add to the cost and timeline of drug
development. Therefore, these studies should only be
performed when there is a clear scientiﬁc rationale to do
so. Figure 2 provides a ﬂow chart for Biogen’s risk-based
approach to determine the need for interaction studies
where the TP is the perpetrator and the SMD is the
victim. If the TP is a cytokine or modulates a cytokine
which can effect regulation of various CYPs, and these
CYPs provide the primary clearance pathway for the co-
administered SMD, then a clinical DI study to examine
potential interaction should be considered. Consideration
should also be given to whether the SMD has a NTR or
required therapeutic drug monitoring. If these conditions
are not met, there is no clear scientiﬁc rationale for
performing a DI study. Likewise, for other TPs such as
mAbs, there must be a clear mechanistic rationale for a
potential interaction with an SMD; otherwise, no inter-
action study should be needed. An adequately powered
population PK approach should also be considered (this
may be more applicable to the mAb stream in the decision
tree).
This “risk-based” approach is science driven, eliminates
the need for unnecessary or low value clinical studies, reduces
cost and time of drug development, and is expected to satisfy
DI requirements. For TP–SMD combinations where a DI
study is indicated, bioanalytical resources can be optimized by
storing samples for analysis until a proof of concept is
established. Biogen’s “collect and hold” strategy for assessing
DI is somewhat unique.
Fig. 1. Genentech’s TP-DI strategy as applied to a mAb during drug development (DI drug interactions,
TP therapeutic protein, SMD small molecule drug, CYP450 cytochrome P450, CL clearance, NTR narrow
therapeutic range, mAb monoclonal antibody, PMC post-marketing commitment, SOC standard of care)
409 Therapeutic Protein–Drug Interaction Study StrategyCentocor’s Strategy to Address TP-DI
The presentation brieﬂy reviewed the pathways for dis-
position ofSMDs and mAbs to exploreplausiblemechanisms of
interaction and discussed technical considerations and strategic
approaches taken at Centocor. As there is no global strategy
availabletoaddresspotentialTP-DIandnoregulatoryguidance
for preclinical and clinical assessment, Centocor has adopted a
risk-based strategy for the assessment of PK-based mAb-DI
(Fig. 3). The integrated risk assessment is designed to utilize
existing data andknowledge,maintainclinicalrelevance,and be
alert and open to new information. A framework is built based
onseveral key factorssuch as thetherapeutic target, therapeutic
windowoftheagents,andplausiblemechanisms.Preclinicaland
Fig. 2. Biogen Idec’s risk-based approach to assess potential for TP-DI. (TP therapeutic protein, mAb
monoclonal antibody, MOA mechanism of action, SMD small molecule drug, CYP450 cytochrome P450,
TDM therapeutic drug monitoring, DI drug interactions, POC proof of concept, NTR narrow therapeutic
range, POP-PK/PD population-PK/PD)
Fig. 3. Centocor’s strategy to address TP-DI (TP-SMD therapeutic protein-small molecule drug
interaction, PK pharmacokinetic, PD pharmacodynamic, DI drug interactions)
410 Girish et al.clinical studies for the assessment of potential mAb-DI are
conducted on a case-by-case basis. Potential applicable
approaches encompass population PK modeling based assess-
ment, dedicated or “cocktail” clinical studies, and mechanism-
based in vitro evaluation.
SESSION III: REGULATORY PERSPECTIVES
European Regulatory Perspective on TP-DI Strategy
The current European Guideline on the investigation
of DI was adopted a decade ago. In April 2010, a draft-
revised guideline was adopted by the Committee for
Medicinal Products for Human Use (CHMP) for release
on a 6-month public comment period (35). The draft
guideline does not contain advice related to TPs. This
was intentional as it was considered difﬁcult to give
detailed advice based on the available knowledge. How-
ever, some advice is given in another speciﬁc guideline
“The CHMP guideline on the clinical investigation of the
pharmacokinetics of therapeutic proteins” published in
2007 (8). This guideline states that some TPs have been
found to cause DI and that the need for DI studies should
be considered on a case-by-case basis. Interaction studies
should be considered when the protein induces changes to
elimination pathways (receptors) also involved in the
elimination of other drugs or when suppression of the
immunological system is likely, as also when there are
possible interactions with endogenous proteins as well as
interactions due to effect on target (e.g., receptor) expres-
sion. It is pointed out that the interaction studies generally
need to be of multiple-dose design.
The DI at an enzyme level observed so far has generally
been of a moderate magnitude. The effects seem mainly
relevant for NTR drugs but some increases in drug clearance
found could also be of clinical relevance for other medicinal
products. In some cases, the effect observed in patients is
actually a normalization of enzyme expression. This makes
translating the effects into practically applicable labeling
advice difﬁcult unless the affected drug is individually titrated.
The recommendation may need to be different depending on
whether the affected drug was initiated before or after the
manifest of the disease.
The optimal study design of a TP-DI study is likely to
be a long duration in vivo investigation, possibly with
repeated DI measurements in the target patient popula-
tion. Due to the challenges of performing such a study, in
vitro methods which may detect the interactions are
warranted as general screening tools. Possibly, cultured
hepatocytes with veriﬁed presence of enzyme regulatory
systems via PXR, CAR, and NF-kβ could be used for
effects via these pathways. However, other interaction
mechanisms may exist, which then also needs veriﬁcation
during the culturing. Other in vitro methods to investigate
the effect on interleukins may be a way forward to screen
for interaction potential of this speciﬁc mechanism. How-
ever, due to the lack of experience with these methods, it is
possible that the results may only be used qualitatively.
According to the labeling of the TPs registered in the
last 5 years on the EU market, PK interaction studies were
not performed with majority of the drugs. Slightly more
Fig. 4. TP–DI and implications for drug development (2). Summary of the types of studies that have been
used during drug development to evaluate therapeutic protein (TP)–small molecule drug (D) interactions.
This includes an evaluation of the effect of TP on D (TP→D) and the effect of D on TP (D→TP). The
broken lines suggest the limited use of in vitro studies for informing in vivo study design or labeling (CYP
cytochrome P450, population PK population pharmacokinetics)
411 Therapeutic Protein–Drug Interaction Study Strategythan one ﬁfth of the TPs had a statement in the labeling
that “Drug interactions were not expected”.As m a l l
percentage of the approved drug applications contained
results from conventional DI studies. However, in the
labeling of almost one tenth of the products, it was stated
that effects on CYP enzymes were expected although not
studied. Another tenth included information from popula-
tion PK analyses.
Evolution of Regulatory Guidance Development by the US
Food and Drug Administration for Small Molecules
and Application to Large Molecule DI
Various intrinsic and extrinsic factors can affect an
individual patient’s drug exposure and response (36). The
US FDA has published several guidance documents
recommending how and when to evaluate these factors,
including DI, during drug development (37). The need to
evaluate DI during drug development cannot be over-
emphasized. Metabolism- and transporter-based DI have
contributed to adverse events with some drugs that were
withdrawn from the US market. Drug labels need to and
have been updated to include information related to DI.
Recent examples include clopidogrel: its interaction with
CYP2C19 inhibitors and the use in patients with deﬁcient
CYP2C19 enzyme activities have been recently added to
its labeling. In addition, developing tools (in vitro
methodologies and pharmacogenetics evaluation) to eval-
uate the role of various ATP-binding cassette and solute
carrier transporters in drug disposition (38) and thereby
safety and efﬁcacy have increased understanding of DI
involving statin drugs [e.g., rosuvastatin and organic anion
transporting polypeptide 1B1 (OATP1B1) and breast
cancer resistance protein]. The US FDA has proposed
various decision trees to help determine when to evaluate
transporter-based DI during drug development (39).
Further, TP-DI studies have been increasingly conducted
(Fig. 4) and included in the labeling (2). Continued
evaluation of their clinical signiﬁcance will help the US
Table I. Summary of Drug Interaction Studies in the US FDA Approved Package Inserts for New Molecular Entity TPs Approved by the End
of February 2010 (Adapted from Reference 1)
Category Dedicated studies Some information No information Total (%)
Cytokines 2 7 2 11 (14)
Growth factors 0 2 8 10 (13)
Enzymes 1 7 9 17 (22)
Monoclonal antibodies 6 13 10 29 (38)
Miscellaneous 0 6 3 9 (12)
Total 9 (12%) 35 (46%) 32 (42%) 76 (100)
Reproduced from (1) with permission from Adis, a Wolters Kluwer business (© Adis Data Information BV 2010. All rights reserved)
Table II. Examples of Labeling Dealing with TP–DI (that Result in Pharmacokinetic Changes)
Drug name Labeling language
1. CYP enzyme modulation by cytokines
and cytokine modulators
Tocilizumab (Actemra) 7 Drug interactions
7.2 Interactions with CYP450 substrates
The effect of tocilizumab on CYP enzymes may be clinically relevant for CYP450 substrates
with narrow therapeutic index, where the dose is individually adjusted. Upon initiation or
discontinuation of ACTEMRA, in patients being treated with these types of medicinal
products, therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g.,
cyclosporine or theophylline) should be performed and the individual dose of the medicinal
product adjusted as needed. Prescribers should exercise caution when ACTEMRA is co-
administered with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g.,
oral contraceptives, lovastatin, atorvastatin, etc. The effect of tocilizumab on CYP450 enzyme
activity may persist for several weeks after stopping therapy [see Clinical Pharmacology (12.3)]
2. Immunosuppressive effect
Inﬂiximab (Remicade) 7 Drug interactions
7.3 Methotrexate (MTX) and other concomitant medications
Concomitant MTX use may decrease the incidence of anti-inﬂiximab antibody production and
increase inﬂiximab concentrations
3. Mechanisms to be elucidated
Palifermin (Kepivance) 7 Drug interactions
Avoid co-administration of palifermin with heparin. If heparin is used to maintain an
intravenous line, rinse the line with saline prior to and after Kepivance administration
Trastuzumab (Herceptin) 7 Drug interactions
In clinical studies, administration of paclitaxel in combination with Herceptin resulted in a 1.5-
fold increase in Trastuzumab serum levels [see Clinical Pharmacology (12.3)]
412 Girish et al.FDA in formulating its recommendations in this area.
Recent advancements in the development of physiologi-
cally-based PK modeling for SMDs has been critical and
has been used to help address questions including in vitro
to in vivo extrapolations and simulations of the extent of
DI under various dosing regimens of the interacting
drugs, in patients with concomitant renal impairment, in
patients with various genotypes of metabolizing enzymes,
etc. (40). Successful collaboration between academia,
industry, and government agencies in this ﬁeld and in
other areas, illustrated by the establishment of the
International Transporter Consortium for developing a
Table III. Examples of Labeling Dealing with TP–DI (that Result in Pharmacodynamic Changes)
Drug name Labeling language
1. Growth factors (Palifermin and G-CSF) and chemotherapy
Palifermin (Kepivance) Drug interactions
Do not administer Kepivance within 24 h before, during infusion of, or within 24 h after
administration of myelotoxic chemotherapy [see Dosage and Administration (2.2) and
Clinical Studies (14)]. In a clinical trial, administration of Kepivance within 24 h of
chemotherapy resulted in increased severity and duration of oral mucositis
Filgrastim (Neupogen) Precautions
Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic
chemotherapy‚ do not use NEUPOGEN® in the period 24 h before through 24 h
after the administration of cytotoxic chemotherapy (see Dosage and Administration)
Pegﬁlgrastim (Neulasta) NEULASTA® should not be administered in the period between 14 days before and
24 h after administration of cytotoxic chemotherapy (see Dosage and
Administration) because of the potential for an increase in sensitivity of rapidly
dividing myeloid cells to cytotoxic chemotherapy
2. Growth factors and myeloablative therapy
Oprelvekin (Neumega) Warnings (Neumega)
Increased toxicity following myeloablative therapy
Neumega is not indicated following myeloablative chemotherapy. In a randomized,
placebo-controlled phase 2 study, the effectiveness of Neumega was not
demonstrated (see Clinical Studies, Study in Patients Following Myeloablative
Chemotherapy). In this study, a statistically signiﬁcant increased incidence in
edema, conjunctival bleeding, hypotension, and tachycardia was observed in
patients receiving Neumega as compared to placebo.
The following severe or fatal adverse reactions have been reported in post-marketing
use in patients who received Neumega following bone marrow transplantation:
ﬂuid retention or overload (e.g., facial edema, pulmonary edema), capillary leak
syndrome, pleural and pericardial effusion, papilledema and renal failure
3. Increased toxicities with concurrent therapy (proleukin and psychotropic, nephrotoxic, myelotoxic,
cardiotoxic or hepatotoxic drugs)
Aldesleukin (Proleukin) Drug interactions
PROLEUKIN may affect central nervous function. Therefore, interactions could occur
following concomitant administration of psychotropic drugs (e.g., narcotics,
analgesics, antiemetics, sedatives, tranquilizers)
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides,
indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g.,
doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with
PROLEUKIN may increase toxicity in these organ systems. The safety and efﬁcacy
of PROLEUKIN in combination with any antineoplastic agents have not been
established
In addition, reduced kidney and liver function secondary to PROLEUKIN treatment
may delay elimination of concomitant medications and increase the risk of adverse
events from those drugs
4. Increased infections with concurrent therapy
Etanercept (Enbrel) Drug Interactions
In a study in which patients with active Rheumatoid Arthritis were treated
for ≤24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious
infections was observed, which was higher than that observed with Enbrel alone
(0%). Two percent of patients treated concurrently with Enbrel and anakinra
developed neutropenia (ANC <1×109/l)
5. Increased myelotoxicity (interferon alfa-2b and myelosuppressive agents)
Interferon alfa-2b (Intron A) Drug interactions
Caution should be exercised when administering INTRON A therapy in combination
with other potentially myelosuppressive agents such as zidovudine
413 Therapeutic Protein–Drug Interaction Study Strategywhite paper for transporters (38), are keys to success in
developing useful informationf o rt h es a f ea n de f f e c t i v e
use of SMDs (41). It is intended that similar efforts be
applicable to TP-DI.
Regulatory Perspectives on TP-DI Evaluation—Case Studies
Table I summarizes DI studies included in the US FDA-
approved package inserts for new molecular entity TPs
approved by the end of February 2010 (1). Various possible
mechanisms of PK TP-DI were presented with examples and
labeling impact (Table II).
1. CYP enzyme modulation by cytokines and cytokine
modulators
Tocilizumab was used as an example to illustrate
the effect of cytokine modulators on CYP enzymes.
CYP enzymes in the liver are downregulated by
infection and inﬂammation stimuli including cyto-
kines such as IL-6. Inhibition of IL-6 signaling in
RA patients treated with tocilizumab may restore
CYP activities to higher levels than those not treated
with tocilizumab leading to increased metabolism of
drugs that are CYP substrates. As stated earlier in this
paper, in vivo studies showed that the exposure of
omeprazole(asubstrateofCYP2C19andCYP3A4)and
simvastatin (a substrate of CYP3A4 and transporter
OATP1B1) decreased 1 week following a single dose of
tocilizumab.
2. Immunosuppressive effect
MTX, an immunosuppressive agent, reduced the
apparent clearance of inﬂiximab likely due to the
reduced incidence of anti-inﬂiximab formation. At
8 weeks after a maintenance dose of 3–10 mg/kg of
inﬂiximab, median inﬂiximab serum concentrations
ranged from approximately 0.5–6 mcg/mL; how-
ever, inﬂiximab concentrations were not detectable
(<0.1 mcg/mL) in patients who tested positive for
antibodies to inﬂiximab (42). The incidence of anti-
inﬂiximab antibody was 21% and 7%, respectively
in the absence and presence of MTX at 12 weeks
after last inﬂiximab infusion at a 3 mg/kg dose
(23).
3. Mechanisms to be elucidated
The mechanism for the observed ﬁvefold increase in
the systemic exposure of palifermin, a recombinant
human keratinocyte growth factor, when it was co-
administered with heparin, has not been fully
elucidated. Also the mechanism for paclitaxel
increasing trastuzumab systemic exposure is not
clear (Table II).
Possible mechanisms of PD interactions were also
discussed with labelling impact (Table III).
CONCLUSIONS
DI studies are regularly conducted with conventional
SMDs, but few DI studies have been performed with TPs.
In this workshop, industry, academic, and regulatory
speakers highlighted important emerging themes for con-
sideration in DI assessment for TPs such as: molecule type,
target, indication, and disease biology. Speakers also
discussed recent reports regarding the regulation of CYP
enzymes and transporters in inﬂammatory states. The use
of cytokines, cytokine modulators, and immunosuppres-
sant-containing combinations in inﬂammatory indications
may have potential for DI, in particular when TPs are
combined with NTR drugs. A question- and risk-based (the
deﬁnition of risk will be individualized) integrated
approach depending on the mechanism of action of TPs
and patient population appears to have evolved and is used
within companies like Genentech, Biogen Idec, Amgen and
Centocor. Critical knowledge gaps and areas needing
further research were identiﬁed (Table IV). The US FDA
is updating its recommendations to sponsors of new drug
applications and biologics license applications who are
conducting in vitro and/or in vivo interaction studies with
TPs (7). This guidance is expected to address some of the
challenges unique to biologics.
Table IV. Summary of Knowledge Gaps and Areas Needing Further
Research
Knowledge gaps
Several knowledge gaps were identiﬁed that require further
cross collaboration between academia, industry and
regulators. While there is extensive literature on the effects
of cytokines and cytokine modulators in CYP
a enzyme
levels (1,2,5,16) there is a knowledge gap in our understanding
of how in vitro assessment of cytokines and cytokine modulators
alter CYP enzyme levels/activity and how this can translate
to meaningful in vivo changes in exposure
￿ Determine appropriateness of in vitro systems to study in vivo TP-DI
b
￿ TP-DI mechanisms proposed need to be validated with actual in
vitro data wherever possible
￿ Technical optimization and validation of in vitro systems for
studying TP-DI
○ Determine what systems/cell types are appropriate for studying
TP-DI
○ Develop methodology that is robust, reproducible and relevant
to in vivo data
○ Develop a more mechanistic understanding of how TPs
c alter
CYP activity in vitro and in vivo
○ Understand whether other drug metabolizing enzymes
(besides CYP) and transporters are involved in TP-DI
￿ Inﬂammation and effect on CYP
○ Better understand how constant and intermittent
inﬂammation could cause a change in cytokines and thereby
affect CYP
○ Understand whether and how this can be translated
into understanding TP-DI in the clinical setting
￿ Give priority to generate in vitro data to grow our knowledge base
○ Priority to (1) cytokines (2) TPs that are cytokine modulators
○ Priority for studying existing proposed mechanisms of TP-DI
○ Priority to understand various mechanism via which TPs could
cause TP-DI
￿ Develop exploratory multiphase/physiological/systems
biology models to study cytokine mediated effect on CYP
￿ Data analyses gap—assess best practice for including
concomitant medications in assessing TP-DI via POP-PK
d
aCYP cytochromes P450
bTP-DI therapeutic protein–drug interactions
cTPs Therapeutic proteins
dPOP-PK population pharmacokinetics
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